Literature DB >> 31176084

High incidence of early onset preeclampsia is probably the rule and not the exception worldwide. 20th anniversary of the reunion workshop. A summary.

Pierre-Yves Robillard1, Gustaaf Dekker2, Gérard Chaouat3, Michael G Elliot4, Marco Scioscia5.   

Abstract

The 11th workshop on Immunology of preeclampsia in Reunion 2018 celebrated its 20th candle In this paper we try to summarize the main tracks of reflections during these two decades. First, of course, the advances in immunology of reproduction in the field of preeclampsia, which was poorly developed 2 decades ago when we first started in 1998. But, this workshop has not been dedicated only to immunology. Second, one of the main reflections has always been, workshop after workshop: "why does preeclampsia exists in humans?" in an evolutionary view, as we have no established natural animal models in the other some 4500 other mammal species. Third, besides the reflections on the biological plausibility of preeclampsia-disease-of-first-pregnancies-at-a-level-of-a-couple (primipaternity rather than primigravidity), i.e. immunology, paternal-maternal conflict, we had to face an apparent conundrum: the human species should have disappeared (almost 40-50% incidence of hypertensive disorders of pregnancy in couples conceiving within the first 4 months of sexual cohabitation). We report then the dialogues we were obliged to have with zoologists who themselves had no clues on our apparent "extravagant sexuality" and strange reproduction (ridiculous low fertility rate of the human female: 25%). Fourth, debates on the main difference between early onset ("rather immunological") and late onset PE ("rather maternal vascular predispositions"). Further, the debate of why high income countries report 90% of their PE being LOP, while other countries describe epidemiologically very high incidences of EOP. Finally, and always present at all workshops, the physiopathology of the reversible systemic maternal vascular inflammation.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Epidemiology; Immunology; Preeclampsia

Mesh:

Year:  2019        PMID: 31176084     DOI: 10.1016/j.jri.2019.05.003

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  6 in total

Review 1.  The etiology of preeclampsia.

Authors:  Eunjung Jung; Roberto Romero; Lami Yeo; Nardhy Gomez-Lopez; Piya Chaemsaithong; Adithep Jaovisidha; Francesca Gotsch; Offer Erez
Journal:  Am J Obstet Gynecol       Date:  2022-02       Impact factor: 8.661

2.  Validation of the 34-week gestation as definition of late onset preeclampsia: Testing different cutoffs from 30 to 37 weeks on a population-based cohort of 1700 preeclamptics.

Authors:  Pierre-Yves Robillard; Gustaaf Dekker; Marco Scioscia; Francesco Bonsante; Silvia Iacobelli; Malik Boukerrou; Thomas C Hulsey
Journal:  Acta Obstet Gynecol Scand       Date:  2020-04-09       Impact factor: 3.636

3.  Gestational weight gain and rate of late-onset preeclampsia: a retrospective analysis on 57 000 singleton pregnancies in Reunion Island.

Authors:  Pierre-Yves Robillard; Gustaaf Dekker; Malik Boukerrou; Brahim Boumahni; Thomas Hulsey; Marco Scioscia
Journal:  BMJ Open       Date:  2020-07-28       Impact factor: 2.692

Review 4.  Reviewing Accuracy of First Trimester Screening for Preeclampsia Using Maternal Factors and Biomarkers.

Authors:  Sarah L Malone; Rani Haj Yahya; Stefan C Kane
Journal:  Int J Womens Health       Date:  2022-09-19

5.  Impact of gestational hypertension and pre-eclampsia on preterm birth in China: a large prospective cohort study.

Authors:  Hang An; Ming Jin; Zhiwen Li; Le Zhang; Hongtian Li; Yali Zhang; Rongwei Ye; Nan Li
Journal:  BMJ Open       Date:  2022-09-27       Impact factor: 3.006

6.  Increased BMI has a linear association with late-onset preeclampsia: A population-based study.

Authors:  Pierre-Yves Robillard; Gustaaf Dekker; Marco Scioscia; Francesco Bonsante; Silvia Iacobelli; Malik Boukerrou; Thomas C Hulsey
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.